血浆p-tau亚型与淀粉样蛋白、tau PET、神经退行性变、血管病理及认知结局的比较
该研究基于Mayo临床衰老研究数据,对200名无痴呆参与者头对头比较了Simoa平台血浆p-tau181、p-tau231与MSD平台p-tau181、p-tau217,分析其与淀粉样蛋白PET、tau PET、神经退行性变、血管病理及认知结局的关联。结果显示各p-tau亚型在淀粉样蛋白PET和tau PET感兴趣区上无差异,但MSD p-tau181和p-tau217在预测内嗅皮层tau PET异常上优于Simoa p-tau181,且MSD p-tau181、MSD p-tau217和Simoa p-tau181与白质高信号体积及白质微结构完整性相关。
要点
- 在无痴呆人群中,血浆p-tau亚型与平台间对淀粉样蛋白和tau PET及MRI血管病理的预测存在细微差异。
- MSD p-tau181和p-tau217预测内嗅皮层tau PET异常优于Simoa p-tau181。
- MSD p-tau181、MSD p-tau217和Simoa p-tau181与白质高信号体积及白质微结构完整性相关。
核心结论
- 在 largely presymptomatic 人群中,血浆p-tau亚型和平台对淀粉样蛋白及tau PET和MRI脑血管与阿尔茨海默病相关病理的预测存在细微差异。
研究设计与样本
- 共200名无痴呆参与者,其中177名认知未受损,23名轻度认知障碍;101名(50.5%)为男性,中位年龄79.5(IQR 71.1-84.1)岁。
主要发现
- 在淀粉样蛋白阳性认知未受损参与者中,Simoa p-tau181中位数较淀粉样蛋白阴性者高49%(2.58 [2.00-3.72] vs 1.73 [1.45-2.13] pg/mL)。
- MSD p-tau181中位数高53%(1.22 [0.91-1.56] vs 0.80 [0.66-0.97] pg/mL),MSD p-tau217中位数高77%(0.23 [0.17-0.34] vs 0.13 [0.09-0.18] pg/mL)。
- Simoa p-tau231中位数高49%(20.21 [15.60-25.41] vs 14.27 [11.27-18.10] pg/mL)。
- 各p-tau亚型在淀粉样蛋白PET和tau PET感兴趣区上无差异。
- 在认知未受损参与者中,MSD p-tau181和MSD p-tau217预测内嗅皮层tau PET异常的AUROC分别为0.80和0.81,均优于Simoa p-tau181的0.70(P分别为.046和.04)。
关键数值与推荐
- 淀粉样蛋白PET异常定义为标准化摄取值比大于1.48。
- 预测准确性用受试者工作特征曲线下面积(AUROC)统计量总结。
临床怎么用
- 临床选用血浆p-tau标志物时需考虑亚型与检测平台差异,MSD p-tau181和p-tau217对tau PET异常预测更优。
- 血浆p-tau181和p-tau217可辅助评估脑淀粉样蛋白及tau病理和脑血管病理。
局限性
- 研究样本主要来自认知未受损人群,结果外推至痴呆阶段需谨慎。
- 样本量有限,仅200名参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed. OBJECTIVE: To conduct a head-to-head comparison of plasma p-tau181 and p-tau231 measured on the single-molecule array (Simoa) platform and p-tau181 and p-tau217 measured on the Meso Scale Discovery (MSD) platform on amyloid and tau positron emission tomography (PET) measures, neurodegeneration, vascular pathology, and cognitive outcomes. DESIGN, SETTING, AND PARTICIPANTS: This study included data from the Mayo Clinic Study on Aging collected from March 1, 2015, to September 30, 2017, and analyzed between December 15, 2020, and May 17, 2021. Associations between the 4 plasma p-tau measures and dichotomous amyloid PET, metaregion of interest tau PET, and entorhinal cortex tau PET were analyzed using logistic regression models; the predictive accuracy was summarized using area under the receiver operating characteristic curve (AUROC) statistic. Of 1329 participants without dementia and with p-tau181 and p-tau217 on MSD, 200 participants with plasma p-tau181 and p-tau231 on Simoa and magnetic resonance imaging and amyloid and tau PET data at the same study visit were eligible. MAIN OUTCOMES AND MEASURES: Primary outcomes included amyloid (greater than 1.48 standardized uptake value ratio) and tau PET, white matter hyperintensities, white matter microstructural integrity (fractional anisotropy genu of corpus callosum and hippocampal cingulum bundle), and cognition. RESULTS: Of 200 included participants, 101 (50.5%) were male, and the median (interquartile range [IQR]) age was 79.5 (71.1-84.1) years. A total of 177 were cognitively unimpaired (CU) and 23 had mild cognitive impairment. Compared with amyloid-negative CU participants, among amyloid-positive CU participants, the median (IQR) Simoa p-tau181 measure was 49% higher (2.58 [2.00-3.72] vs 1.73 [1.45-2.13] pg/mL), MSD p-tau181 measure was 53% higher (1.22 [0.91-1.56] vs 0.80 [0.66-0.97] pg/mL), MSD p-tau217 measure was 77% higher (0.23 [0.17-0.34] vs 0.13 [0.09-0.18] pg/mL), and Simoa p-tau231 measure was 49% higher (20.21 [15.60-25.41] vs 14.27 [11.27-18.10] pg/mL). There were no differences between the p-tau species for amyloid PET and tau PET metaregions of interest. However, among CU participants, both MSD p-tau181 and MSD p-tau217 more accurately predicted abnormal entorhinal cortex tau PET than Simoa p-tau181 (MSD p-tau181: AUROC, 0.80 vs 0.70; P = .046; MSD p-tau217: AUROC, 0.81 vs 0.70; P = .04). MSD p-tau181 and p-tau217 and Simoa p-tau181, but not p-tau231, were associated with greater white matter hyperintensity volume and lower white matter microstructural integrity. CONCLUSIONS AND RELEVANCE: In this largely presymptomatic population, these results suggest subtle differences across plasma p-tau species and platforms for the prediction of amyloid and tau PET and magnetic resonance imaging measures of cerebrovascular and Alzheimer-related pathology.
引用
- Mielke MM, Frank RD, Dage JL, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021. PMID: 34309632. doi:10.1001/jamaneurol.2021.2293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。